Parade on MSN6d
'I Was Diagnosed With Pulmonary Arterial Hypertension At 25—This Was the First Unexpected Symptom I Experienced'Katrina Berry was 24 years old when she first started experiencing symptoms of pulmonary arterial hypertension (PAH), a ...
Regarded mostly as a lung disease, PAH is often in people with fewer nail fold capillaries, suggesting a disease of the small ...
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension registry (CTEPH), conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term ...
In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...
Tyvaso is well tolerated by PH patients with different types, and stopping raises by five times the risk of disease worsening ...
The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.
Tectonic recently announced the U.S. Food and Drug Administration cleared its Investigational New Drug application for TX45. Screening for the Phase 2 APEX clinical trial has been initiated and ...
Researchers identified several inflammatory circulating proteins that could be useful biomarkers for predicting outcomes in ...
Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:BAYRY) exclusive worldwide rights to ...
The move will enable the country’s more than 100 million chronic pulmonary disease patients to access free annual check-ups.
A recent retrospective study published in the The Journal of Pediatrics unveiled the potential benefits of using epoprostenol ...
Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback